Novo launches type 2 diabetes pill in UK after NICE waives review
pharmaphorum
SEPTEMBER 1, 2020
Novo Nordisk has launched its type 2 diabetes pill Rybelsus (semaglutide) in the UK, after cost-effectiveness watchdog NICE decided that there was no need to review it. The most common adverse reactions were nausea, diarrhoea and hypoglycemia when used with insulin and/or sulfonylurea.
Let's personalize your content